Technologies for Genomic Medicines

Sangamo is developing new genomic medicines which may address the underlying mistakes in DNA that lead to some genetic diseases.

Unlocking the potential for precise genetic cures

Since our founding in 1995, Sangamo has been a leader in genomic medicine research and development. With our experience developing gene editing technologies, we have also become experts in gene therapy, cell therapy, and genome regulation technology. This range of approaches allows us to connect the underlying biology of the disease to the appropriate technology.

delivery and manufacturing

We use both adeno-associated virus (AAV) and mRNA to deliver our therapeutics and continue to develop and refine these platforms as well as our manufacturing processes for therapeutic cell production. Using our molecular biology and AAV expertise, we are also developing gene therapy approaches for key indications.

NEXT GENERATION ZFNS

Our scientists are continuously aiming to improve our ZFN technology around the key genome editing parameters of precision, efficiency, and specificity. Learnings from the application of zinc finger technology in the clinic informs our research priorities with regards to ZFN improvements.

A ROBUST PIPELINE OF GENOMIC MEDICINES

Our Pipeline

Sangamo presentations + Publications

Our broad collection of publications, authored by our own scientists, collaborators, and others, contains original research articles and review articles that are relevant to our ZFP technology and its many applications.

 

VIEW PRESENTATIONS VIEW PUBLICATIONS